Alkermes plc released a summary of its Q2 2026 [1] earnings call detailing new pricing strategies and the termination of a generic drug agreement.

These developments signal a shift in how the company intends to position its products against competitors and manage its intellectual property portfolio. By monitoring rival entries, the company aims to maximize revenue while maintaining market viability in the orexin class.

Management said that the expected market entry of a product from Takeda will be a pivotal moment for the industry. According to the company, this entry will establish a "price corridor" for the orexin class, which Alkermes will use to inform its own pricing strategy, management said [1].

This approach suggests that Alkermes is waiting for a market benchmark to be set before finalizing its own costs. The orexin class represents a specific pharmacological target, and the resulting price corridor will likely dictate the accessibility and profit margins for all players in that sector.

In a separate strategic move, the company changed its relationship with Amneal. Alkermes management said the company terminated its authorized generic agreement for VIVITROL with Amneal [1].

Authorized generic agreements typically allow a brand-name company to let a generic manufacturer sell a version of the drug to maintain a presence in the lower-cost market. The termination of this specific deal indicates a change in how Alkermes intends to manage the lifecycle, and distribution, of VIVITROL.

These updates come as part of the broader financial reporting for the second quarter of 2026 [1]. The company is now focusing on aligning its commercial goals with the evolving competitive landscape of the pharmaceutical market.

“Takeda's expected market entry will establish a 'price corridor' for the orexin class”

The move to anchor pricing to a competitor's entry suggests a cautious approach to market penetration for the orexin class, avoiding a premature price war. Simultaneously, ending the authorized generic agreement for VIVITROL may indicate that Alkermes believes it can either maintain higher margins without a partner or is shifting its distribution strategy to regain more direct control over the product's market share.